Chemomab Therapeutics (CMMB) Other Accumulated Expenses (2017 - 2019)

Chemomab Therapeutics' Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $2.3 million for Q4 2019.

• Quarterly Other Accumulated Expenses rose 34.58% year-over-year to $2.3 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $2.3 million (up 34.58% YoY) and the FY2019 annual result came in at $2.3 million, up 34.58% from the prior year.
• Other Accumulated Expenses was $2.3 million for Q4 2019 at Chemomab Therapeutics, down from $3.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.8 million in Q3 2019 and bottomed at $1.6 million in Q2 2019.
• A 3-year average of $2.4 million and a median of $2.3 million in 2019 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2018 — Other Accumulated Expenses dropped 28.35% — and 2019, when it jumped 34.58%.
• Chemomab Therapeutics' Other Accumulated Expenses stood at $2.4 million in 2017, then fell by 28.35% to $1.7 million in 2018, then jumped by 34.58% to $2.3 million in 2019.
• Business Quant data shows CMMB's Other Accumulated Expenses at $2.3 million in Q4 2019, $3.8 million in Q3 2019, and $1.6 million in Q2 2019.